GLP-1R agonists’ diabetes and obesity market forecast to reach $125 billion in 7MM by 2033

17 May 2024

Glucagon-like peptide-1 (GLP-1) receptor agonists are a class of incretin mimetic medicines for the treatment of type 2 diabetes and obesity, and an ever more active sector for the pharma industry.

With the obesity and type 2 diabetes markets growing at unprecedented rates, the GLP-1 receptor agonists market is also growing. GLP-1 receptor agonist sales for the type 2 diabetes and obesity markets are forecast to reach over $125 billion in the seven major markets (7MM; USA, Germany, France, Italy, Spain, UK and Japan ) by 2033, according to pharma analytics company GlobalData.

GlobalData’s latest report “ Glucagon-like peptide-1 (GLP-1) receptor agonists in type 2 diabetes and obesity: Seven-Market Forecast and Market analysis,” reveals that GLP-1 receptor agonists will dominate the metabolic diseases space in the next 10 years. These medicines are already popular, and key opinion leaders (KOLs) interviewed by GlobalData said that patients usually ask their doctors for these specific medicines.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK